NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome (original) (raw)

• Chiorazzi N, Rai KR, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815.
  Article CAS Google Scholar
• Tam CS, Keating MJ . Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2010; 7: 521–532.
  Article CAS Google Scholar
• Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37–50.
  Article CAS Google Scholar
• Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101–105.
  Article CAS Google Scholar
• Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47–52.
  Article CAS Google Scholar
• Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389–1401.
  Article CAS Google Scholar
• Di Ianni M, Baldoni S, Rosati E, Ciurnelli R, Cavalli L, Martelli MF et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol 2009; 146: 689–691.
  Article CAS Google Scholar
• Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521–529.
  Article CAS Google Scholar
• Sportoletti P, Baldoni S, Cavalli L, Del PB, Bonifacio E, Ciurnelli R et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 2010; 151: 404–406.
  Article Google Scholar
• Müller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H . Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, PIleri SA, Stein H, Thiele J, Vardiman JW, (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon, 2008; pp 180–182.
  Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
  Article CAS Google Scholar
• Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956–964.
  Article CAS Google Scholar
• Bosch F, Ferrer A, Villamor N, Gonzalez M, Briones J, Gonzalez-Barca E et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008; 14: 155–161.
  Article CAS Google Scholar
• Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007; 21: 1–3.
  Article CAS Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317.
  Article CAS Google Scholar
• Dickman PW, Sloggett A, Hills M, Hakulinen T . Regression models for relative survival. Stat Med 2004; 23: 51–64.
  Article Google Scholar
• Ederer F, Axtell LM, Cutler SJ . The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101–121.
  CAS PubMed Google Scholar
• Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.
  Article Google Scholar
• Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119: 329–331.
  Article CAS Google Scholar
• Shedden K, Li Y, Ouillette P, Malek SN . Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34. Leukemia 2012; 26: 1108–1110.
  Article CAS Google Scholar
• De Keersmaecker K, Michaux L, Bosly A, Graux C, Ferreiro JF, Vandenberghe P et al. Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL. Blood 2012; 119: 3864–3866.
  Article CAS Google Scholar
• Schuh A, Becq J, Humphray S, Alexa A, Burns A, Clifford R et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012; 120: 4191–4196.
  Article CAS Google Scholar
• Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012; 97: 437–441.
  Article CAS Google Scholar
• Lopez C, Delgado J, Costa D, Conde L, Ghita G, Villamor N et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes Cancer 2012; 51: 881–889.
  Article CAS Google Scholar
• Bea S, Lopez-Guillermo A, Ribas M, Puig X, Pinyol M, Carrio A et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter’s syndrome). Am J Pathol 2002; 161: 957–968.
  Article CAS Google Scholar
• Cobo F, Martinez A, Pinyol M, Hernandez L, Gomez M, Bea S et al. Multiple cell cycle regulator alterations in Richter’s transformation of chronic lymphocytic leukemia. Leukemia 2002; 16: 1028–1034.
  Article CAS Google Scholar
• Rossi D, Gaidano G . Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009; 27: 1–10.
  Article CAS Google Scholar
• Tsimberidou AM, Keating MJ . Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216–228.
  Article CAS Google Scholar
• Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol 2012; 158: 426–429.
  Article CAS Google Scholar
• Aster JC, Blacklow SC, Pear WS . Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 2011; 223: 262–273.
  Article CAS Google Scholar
• Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268–281.
  Article CAS Google Scholar
• Lobry C, Oh P, Aifantis I . Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011; 208: 1931–1935.
  Article CAS Google Scholar
• Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG . The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111: 846–855.
  Article CAS Google Scholar
• Lopez-Guerra M, Colomer D . NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. Expert Opin Ther Targets 2010; 14: 275–288.
  Article CAS Google Scholar
• Palomero T, Ferrando A . Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res 2008; 14: 5314–5317.
  Article CAS Google Scholar
• Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50–58.
  Article CAS Google Scholar
• Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9: 1618–1628.
  Article CAS Google Scholar
• Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464: 1052–1057.
  Article CAS Google Scholar